bicyclol: Clinical Trials

4 trials of bicyclol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 unknown, 1 completed. 1 Not applicable, 1 Phase 2, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Not applicable1Unknown 1
Phase 21Completed 1
Phase 31Unknown 1

Follow bicyclol: new trials by email Literature Review of bicyclol trials Research Report on bicyclol

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Bicyclol in the Treatment of Antineoplastic Drug-induced Liver Injury.
Bicyclol tablets - Drug-Induced Acute Liver Injury
Not applicableUnknownTianjin Medical University Cancer Institute and Hospital54052022-05-012023-02-03
The Multi-Center, Randomized, Double-blind, Positive Controlled Clinical Trial of Bicyclol in the Treatment of Acute DILI
bicyclol, 25mg/ tablet, polyene phosphatidylcholine capsules, 228mg/ particle. - Drug-Induced Acute Liver Injury
Phase 3UnknownDrug Induced Liver Disease Study Group3602021-12-202022-08-04
Clinical Pharmacokinetics of TKIs in Chinese Patients of Hepatitis B (HBV)
Entecavir 1Mg Oral Tablet - Non Small Cell Lung Cancer, Hepatitis B
UnknownAffiliated Cancer Hospital & Institute of Guangzhou Medical University3002018-05-222018-09-28
The Multi Center, Randomized, Double-blind, Positive Controlled Study of Bicyclol in the Treatment of Acute DILI
bicyclol tablet 25mg, bicyclol tablet 50mg, polyene phosphatidylcholine capsule 456mg - Drug-Induced Acute Liver Injury
Phase 2CompletedDrug Induced Liver Disease Study Group2442017-08-182020-04-28

Conditions studied

Chemical and Drug Induced Liver Injury (3)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Hepatitis B (1)

Sponsors

Drug Induced Liver Disease Study Group (2)  ·  Affiliated Cancer Hospital & Institute of Guangzhou Medical University (1)  ·  Tianjin Medical University Cancer Institute and Hospital (1)

Countries

China (4)

Top investigators

Chengwei Chen (2)  ·  Yimin Mao (2)  ·  Shuzhong Cui, MD (1)  ·  Wei Lu, M.D (1)

Results publications

PMID 35567757